Affordable Access

Access to the full text

Potential clinical biomarkers in rheumatoid arthritis with an omic approach

  • Puentes-Osorio, Yolima1, 2
  • Amariles, Pedro1
  • Calleja, Miguel Ángel3
  • Merino, Vicente3
  • Díaz-Coronado, Juan Camilo4
  • Taborda, Daniel5
  • 1 Antioquia University, Medellín, Colombia , Medellín (Colombia)
  • 2 5 , Sevilla (Spain)
  • 3 University Hospital Virgin of Macarena, Sevilla, Spain , Sevilla (Spain)
  • 4 Artmédica IPS, Medellín, Colombia , Medellín (Colombia)
  • 5 Pharmacogenomic Center, Medellín, Colombia , Medellín (Colombia)
Published Article
Autoimmunity Highlights
BioMed Central
Publication Date
May 31, 2021
DOI: 10.1186/s13317-021-00152-6
Springer Nature


ObjectiveTo aid in the selection of the most suitable therapeutic option in patients with diagnosis of rheumatoid arthritis according to the phase of disease, through the review of articles that identify omics biological markers.MethodsA systematic review in PubMed/Medline databases was performed. We searched articles from August 2014 to September 2019, in English and Spanish, filtered by title and full text; and using the terms "Biomarkers" AND “Rheumatoid arthritis".ResultsThis article supplies an exhaustive review from research of objective measurement, omics biomarkers and how disease activity appraise decrease unpredictability in treatment determinations, and finally, economic, and clinical outcomes of treatment options by biomarkers’ potential influence. A total of 122 articles were included. Only 92 met the established criteria for review purposes and 17 relevant references about the topic were included as well. Therefore, it was possible to identify 196 potential clinical biomarkers: 22 non-omics, 20 epigenomics, 33 genomics, 21 transcriptomics, 78 proteomics, 4 glycomics, 1 lipidomics and 17 metabolomics.ConclusionA biomarker is a measurable indicator of some, biochemical, physiological, or morphological condition; evaluable at a molecular, biochemical, or cellular level. Biomarkers work as indicators of physiological or pathological processes, or as a result of a therapeutic management. In the last five years, new biomarkers have been identified, especially the omics, which are those that proceed from the investigation of genes (genomics), metabolites (metabolomics), and proteins (proteomics). These biomarkers contribute to the physician choosing the best therapeutic option in patients with rheumatoid arthritis.

Report this publication


Seen <100 times